Synartro
Developing injection treatments that provide local slow release with minimal systemic burden
Developing injection treatments that provide local slow release with minimal systemic burden
Synartro is a Swedish biotechnology startup established in 2011. The company's mission revolves around developing localized injection treatments with an emphasis on providing sustained efficacy while minimizing systemic side-effects. This is achieved through a unique patented delivery technology combined with existing proven drugs.
The main focus of Synartro's pre-clinical lead program is a revolutionary therapy utilizing their compound SYN321 for the treatment of osteoarthritis (OA), a condition that currently leaves up to 50% of patients without adequate pain relief.
The startup secured a €3.40M Series A investment on 30th September 2021, with the primary investor being Sciety. This investment signifies a strong validation of the potential of Synartro's innovative approach to revolutionize treatment options in the biotechnology sector. With their promising technology and focus on addressing unmet medical needs, Synartro presents a compelling opportunity for venture capital firms seeking to invest in cutting-edge pharmaceutical solutions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | €3.40M | 1 | Sciety | 30 Sep 2021 |
| Series A | €1.70M | 1 | Sciety | 30 Sep 2020 |
| Seed Round | €565.00K | 1 | Sciety | 01 May 2020 |
No recent news or press coverage available for Synartro.
We care about your data, and we'd love to use cookies make your experience better.
